TriangleCisplatin (NCT06445114)
Cisplatin trial for Oropharyngeal Cancer (NCT06445114). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with HPV-associated oropharyngeal squamous-cell cancer, T0–T3N0–N2 without distant spread, having complete visible-disease removal and neck dissection. Selected unknown-primary cancers qualify; postoperative risk features are required.
The idea: HPV DNA measurements and surgical pathology determine treatment intensity. Patients receive thirty, forty, or fifty gray of radiation with weekly cisplatin, which damages DNA. Systemic treatment may be modified if cisplatin is unsuitable. Researchers test two-year progression-free survival using reduced postoperative treatment.
This phase 2 study plans 50 patients. Zachary Zumsteg leads at Cedars-Sinai; four US locations recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.